For example, if the main driver of the treatment choice is out-of-pocket cost, a sulfonylurea or thiazolidinedione (TZD) might be considered as they are currently reimbursed in China; if the main concern is to avoid hypoglycemia, glucagon-like peptide-1 receptor agonist (GLP-1 RAs), sodium-glucose cotransporter two inhibitor (SGLT2i), dipeptidyl peptidase IV inhibitor (DPP-4i), or a thiazolidinediones (TZD) might be preferred (Doyle-Delgado et al., 2020). This evidence concerns the gene GLP1R and Hypoglycemia.